GlycoNex

GlycoNex FCF Margin

The Free Cash Flow Margin of GlycoNex (4168.TWO) as of Nov 4, 2026 is -456.57 %. In the previous year, Free Cash Flow Margin was -1,749.84 % — a change of -73.91% (higher).

FCF Margin

-456.57 %

YoY

-73.91%

Last updated:

Free Cash Flow Margin of GlycoNex is 2025 -456.57 % . Free Cash Flow Margin of GlycoNex was 2024 -1,749.84 % . It decreases by -73.91% higher compared to the previous year.

The GlycoNex FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-19,822.35 TWD
Jan 1, 2019
-24,669.48 TWD
Jan 1, 2020
-32,697.12 TWD
Jan 1, 2021
-2,697.72 TWD
Jan 1, 2022
-585.80 TWD
Jan 1, 2023
-8,156.65 TWD
Jan 1, 2024
-1,749.84 TWD
Jan 1, 2025
-456.57 TWD
The GlycoNex FCF Margin history
YEARFCF MarginYoY
-456.57 %-73.91%
-1,749.84 %-78.55%
-8,156.65 %+1,292.40%
-585.80 %-78.29%
-2,697.72 %-91.75%
-32,697.12 %+32.54%
-24,669.48 %+24.45%
-19,822.35 %-27.85%
-27,475.08 %-73.18%
-102,453.97 %+846.46%
-10,824.92 %+631.25%
-1,480.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlycoNex Stock analysis

What does GlycoNex do? GlycoNex, Inc. develops anti-cancer monoclonal antibodies and bio-similar drugs, offering licensing for monoclonal antibody targets and carbohydrate antigen and protein drug services. The company targets domestic and Asian markets, distributing its products through these regions. Revenue comes from drug development, licensing agreements, and service provision for antibody targets and related biotech solutions. GlycoNex focuses on anti-cancer monoclonal antibody new drugs and bio-similar drugs, with services including carbohydrate antigen and protein drug related offerings. The firm serves domestic and overseas markets in Asia, generating income from product development, licensing, and specialized biotech services. Its business model relies on developing and commercializing innovative cancer treatments and related services in key Asian markets. The company's revenue streams include the development of anti-cancer monoclonal antibody new drugs, bio-similar drugs, and the licensing of monoclonal antibody targets. Services related to carbohydrate antigen and protein drug solutions are also part of the business, distributed across domestic and Asian markets to generate income from pharmaceutical innovation and biotech service contracts. GlycoNex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlycoNex stock

Free Cash Flow Margin of GlycoNex is -456.57 % in 2025.

Free Cash Flow Margin of GlycoNex changed from -1,749.84 % to -456.57 %, representing a -73.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin GlycoNex since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's GlycoNex with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — GlycoNex

All Key Metrics — GlycoNex